GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Change In Payables And Accrued Expense

Chordia Therapeutics (TSE:190A) Change In Payables And Accrued Expense : 円0.00 Mil (TTM As of Feb. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Change In Payables And Accrued Expense?

Chordia Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2025 was 円0.00 Mil. It means Chordia Therapeutics's Accounts Payable & Accrued Expense stayed the same from Aug. 2024 to Feb. 2025 .

Chordia Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Aug. 2024 was 円0.00 Mil. It means Chordia Therapeutics's Accounts Payable & Accrued Expense stayed the same from Aug. 2023 to Aug. 2024 .

Chordia Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Chordia Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Change In Payables And Accrued Expense Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Change In Payables And Accrued Expense
- - - -

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25
Change In Payables And Accrued Expense Get a 7-Day Free Trial - - - - -

Chordia Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordia Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
TSE:4978 TSE:4579 TSE:4588 TSE:4599 TSE:7776 TSE:4880 TSE:4888 TSE:7096 TSE:4583 TSE:206A VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Website
https://www.chordiatherapeutics.com
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines